Poor Concentration: What Could Be Causing It

Why the Differential Matters

Concentration is not a single cognitive function. It recruits sustained attention, working memory, and executive control, each of which depends on distinct neurochemical pathways and brain regions. When a patient reports "trouble focusing," the symptom could originate from dopaminergic underactivity (as in ADHD), serotonergic disruption (depression), metabolic slowing (hypothyroidism), intermittent hypoxia (sleep apnea), or something else entirely.

A 2022 BMJ Best Practice review of cognitive complaints in primary care noted that the most common missed diagnoses were obstructive sleep apnea, adult ADHD, and subclinical hypothyroidism [1]. The review recommended a structured approach: sleep history, mood screen, medication reconciliation, and a short panel of blood tests before any neuropsychological referral. Getting the sequence right avoids months of unnecessary specialist visits. It also prevents the reflexive prescription of stimulants for what may be a thyroid or sleep problem.

The sections below walk through the most common and most overlooked causes, organized by system.

Thyroid Dysfunction

Hypothyroidism is one of the most treatable causes of poor concentration. The thyroid sets the metabolic rate for every organ, including the brain. When free T4 drops, cerebral glucose metabolism falls with it.

A cross-sectional analysis of 5,962 adults in the Colorado Thyroid Disease Prevalence Study found that even subclinical hypothyroidism (TSH 5.1 to 10 mIU/L) was associated with impaired memory and slower processing speed compared to euthyroid controls [2]. The American Thyroid Association (ATA) guidelines state that "cognitive symptoms including difficulty concentrating, mental slowing, and impaired working memory are among the most frequently reported complaints in patients with overt hypothyroidism" [3]. Levothyroxine replacement typically restores cognitive performance within 3 to 6 months when TSH normalizes.

Hyperthyroidism also disrupts focus, though the mechanism differs. Excess thyroid hormone produces anxiety, distractibility, and sleep fragmentation. A TSH below 0.1 mIU/L with elevated free T4 should prompt evaluation for Graves disease or toxic nodular goiter. The fix is different (methimazole, radioactive iodine, or surgery), but the cognitive recovery trajectory is similar once levels stabilize [3].

Screening is simple. A serum TSH catches both directions. If TSH is abnormal, add free T4 and thyroid peroxidase antibodies.

Sleep Disorders

Sleep is the most underrated variable in cognitive performance. A single night of 4 hours of sleep produces attention deficits comparable to a blood alcohol concentration of 0.10%, above the legal driving limit in every U.S. state [4].

Obstructive sleep apnea deserves special attention. It affects roughly 25% of men and 10% of women, and a large proportion remain undiagnosed. The Wisconsin Sleep Cohort Study, tracking 1,522 adults over two decades, found that untreated moderate-to-severe OSA was associated with significant declines in psychomotor vigilance, working memory, and executive function [5]. CPAP therapy improved attention within 2 to 6 weeks in the APPLES trial (N=1,105), though memory gains took longer [6].

Red flags for OSA include snoring, witnessed apneas, a neck circumference greater than 17 inches in men or 16 inches in women, and excessive daytime sleepiness (Epworth Sleepiness Scale score above 10). The STOP-BANG questionnaire can be administered in under 2 minutes. A score of 5 or more warrants polysomnography.

Chronic insomnia, independent of OSA, also degrades concentration. Cognitive behavioral therapy for insomnia (CBT-I) has stronger long-term evidence than sedative-hypnotics for both sleep quality and daytime cognitive function [7].

Depression and Anxiety

The DSM-5 lists "diminished ability to think or concentrate" as one of nine diagnostic criteria for major depressive disorder (MDD). This is not a soft symptom. Neuroimaging studies show reduced dorsolateral prefrontal cortex activation during working memory tasks in depressed patients, even when overall symptom severity is mild [8].

A meta-analysis of 24 studies (N=784 MDD patients, 727 controls) published in Psychological Medicine found that depressed individuals performed 0.6 standard deviations below controls on measures of attention and executive function [8]. That effect size is clinically meaningful. It translates to real difficulty following conversations, reading for comprehension, and managing multi-step tasks.

Generalized anxiety disorder (GAD) impairs concentration through a different pathway: attentional hijacking. Worry consumes working memory bandwidth. The Penn State Worry Questionnaire and GAD-7 are quick screens.

Dr. Madhukar Trivedi, professor of psychiatry at UT Southwestern, has noted that "residual cognitive impairment, particularly poor concentration, is the most common reason patients with treated depression still cannot return to full occupational function" [9]. SSRIs improve mood but have a variable track record on cognition. Vortioxetine (Trintellix) is the only antidepressant with FDA-reviewed data specifically on cognitive function in MDD, based on the CONNECT and FOCUS trials [9].

ADHD in Adults

Adult ADHD is real, common, and commonly missed. The estimated prevalence in U.S. adults is 4.4%, according to the National Comorbidity Survey Replication (N=3,199) [10]. Women are disproportionately underdiagnosed because the predominantly inattentive presentation (daydreaming, disorganization, losing things) draws less clinical attention than the hyperactive-impulsive subtype.

Diagnosis requires evidence that symptoms began before age 12 and cause impairment in two or more settings. The Adult ADHD Self-Report Scale (ASRS-v1.1) is a validated 6-item screen that takes under 3 minutes. A positive screen should prompt a full clinical interview, not immediate pharmacotherapy.

First-line treatment is a stimulant: methylphenidate or mixed amphetamine salts. Effect sizes for inattention symptoms are large (Cohen's d = 0.9 to 1.3 for stimulants vs. placebo), exceeding the effect sizes of most psychiatric medications for their respective indications [11]. Non-stimulant options include atomoxetine (Strattera) and viloxazine (Qelbree). Stimulant prescribing requires cardiovascular screening (blood pressure, heart rate, personal and family cardiac history) per American Academy of Pediatrics and APA guidelines.

A critical clinical point: if a patient has never responded to stimulants or shows late-onset "ADHD" after age 40 with no childhood history, reconsider the diagnosis. Sleep apnea, thyroid disease, and perimenopause can mimic ADHD almost perfectly.

Nutritional Deficiencies

Iron deficiency is the world's most common nutritional deficiency, and its cognitive effects appear before hemoglobin drops into the anemic range. A ferritin level below 30 ng/mL, even with a normal CBC, is associated with impaired attention, slower reaction time, and reduced verbal learning in premenopausal women [12]. Iron supplementation (ferrous sulfate 325 mg daily or every other day) improves cognitive scores within 8 to 12 weeks when ferritin normalizes.

Vitamin B12 deficiency follows a similar pattern. Serum B12 levels below 300 pg/mL can produce fatigue, mental slowing, and poor concentration well before megaloblastic anemia or neuropathy appear [13]. Populations at higher risk include adults over 60 (reduced intrinsic factor), vegans, patients on metformin (which impairs B12 absorption in roughly 30% of long-term users), and those on chronic proton pump inhibitors.

Vitamin D may also play a role, though the evidence is weaker. A 2019 meta-analysis of 26 observational studies found an association between low 25-hydroxyvitamin D and poorer cognitive performance, but supplementation trials have not consistently shown improvement [14]. Check 25-OH vitamin D if the patient has risk factors (limited sun, dark skin, obesity, malabsorption), but do not attribute concentration problems to low vitamin D alone.

A reasonable screening panel for nutritional causes: CBC with differential, ferritin, serum B12, and folate.

Hormonal Shifts: Perimenopause and Low Testosterone

Estrogen modulates acetylcholine, serotonin, and dopamine, all of which support attention and memory. During the menopausal transition, fluctuating and declining estradiol levels produce subjective cognitive complaints in roughly 60% of women, according to the Study of Women's Health Across the Nation (SWAN) [15]. The SWAN cohort (N=2,362) documented measurable declines in processing speed and verbal memory during the perimenopausal window, with partial recovery in the postmenopausal period.

Hormone therapy (HT) with transdermal estradiol, initiated in early menopause (the "timing hypothesis"), has shown modest cognitive benefits in the KEEPS-Cog trial and the ELITE trial [16]. The Endocrine Society's 2015 position statement supports HT for symptomatic women under 60 or within 10 years of menopause onset, noting that vasomotor symptom relief and improved sleep may be the primary mechanisms behind cognitive improvement.

In men, testosterone influences verbal memory, spatial cognition, and processing speed. The Testosterone Trials (TTrials, N=788 men aged 65 and older with low testosterone) found that testosterone gel improved spatial memory but not other cognitive domains over 12 months [17]. The Endocrine Society recommends measuring morning total testosterone in men with symptoms of hypogonadism (fatigue, low libido, poor concentration). Two measurements below 300 ng/dL confirm the diagnosis.

These hormonal evaluations should be considered early in the workup for patients in the right age and symptom profile. They are not last-resort tests.

Medications That Impair Concentration

Sometimes the cause is in the medicine cabinet. Over 100 commonly prescribed drugs list cognitive impairment or "difficulty concentrating" as a known adverse effect. The American Geriatrics Society (AGS) Beers Criteria, updated in 2023, identifies multiple drug classes with strong anticholinergic or central nervous system effects that impair cognition [18].

The worst offenders by class:

Anticholinergics. Diphenhydramine (Benadryl), oxybutynin, and first-generation antihistamines. A large prospective cohort study (N=3,434) in JAMA Internal Medicine found that cumulative anticholinergic use over 10 years was associated with a 54% increased risk of dementia [19]. Even short-term use impairs attention.

Benzodiazepines. Alprazolam, lorazepam, and clonazepam reduce psychomotor speed and working memory. The effect is dose-dependent and worse in older adults.

Opioids. Both acute and chronic opioid use impair executive function and sustained attention.

Beta-blockers. Propranolol crosses the blood-brain barrier and can cause fatigue and mental slowing. Atenolol and metoprolol succinate are less lipophilic and generally better tolerated cognitively.

Gabapentinoids. Gabapentin and pregabalin at higher doses produce sedation and cognitive blunting.

A medication reconciliation, including over-the-counter supplements and "PM" formulations containing diphenhydramine, is a non-negotiable step in evaluating concentration complaints.

Other Medical Conditions to Consider

Several systemic conditions can present with poor concentration as a prominent or even leading symptom.

Type 2 diabetes and insulin resistance. Hyperglycemia impairs hippocampal function. A 2021 Lancet Diabetes & Endocrinology meta-analysis of 14 longitudinal studies found that type 2 diabetes was associated with a 60% increased risk of cognitive decline over 5 years [20]. HbA1c above 7% correlates with worse performance on attention tasks even in patients under 60.

Chronic kidney disease (CKD). Uremic encephalopathy begins subtly. Concentration problems and slowed processing are often the earliest signs. eGFR below 45 mL/min/1.73m2 is the threshold where cognitive effects become measurable [21].

Autoimmune conditions. Systemic lupus erythematosus (SLE) produces "lupus fog" in up to 80% of patients. Hashimoto thyroiditis can impair cognition even when TSH is within normal limits if thyroid antibodies are elevated [22].

Long COVID. Persistent cognitive dysfunction after SARS-CoV-2 infection has been documented in multiple cohorts. A UK Biobank substudy (N=785) found measurable cognitive decline equivalent to 3 years of aging in those with prior COVID-19 infection [23]. There is no validated treatment yet; management focuses on cognitive rehabilitation and treating comorbid sleep, mood, and autonomic symptoms.

Building the Diagnostic Workup

The most efficient evaluation follows a structured sequence rather than a scattershot panel.

Start with three questions: How is sleep? What is the mood? What medications are in use (including OTC)? These alone narrow the differential by at least 50%.

Next, order targeted labs: TSH, CBC, ferritin, B12, fasting glucose, and HbA1c. Add a basic metabolic panel if CKD is a concern. In women over 40 with irregular cycles, check FSH and estradiol. In men with fatigue and low libido, measure morning total testosterone. If symptoms are episodic and associated with palpitations or weight changes, thyroid antibodies and free T4 are warranted.

Validated screening tools speed the process:

• PHQ-9 for depression (score of 10 or above suggests moderate MDD)
• GAD-7 for anxiety
• ASRS-v1.1 for adult ADHD
• STOP-BANG for sleep apnea
• Epworth Sleepiness Scale for daytime somnolence

If the initial workup is unrevealing, consider formal neuropsychological testing. This is the gold standard for distinguishing ADHD from mood-related cognitive impairment from early neurodegenerative disease. A comprehensive battery takes 3 to 6 hours and provides a quantified cognitive profile.

Dr. Ronald Petersen, director of the Mayo Clinic Alzheimer's Disease Research Center, has stated that "the single most important step in evaluating a cognitive complaint is a thorough medication review and basic metabolic screen, because reversible causes are far more common than neurodegeneration in patients under 65" [24].

Referral to neurology is appropriate when there is progressive decline over 6 months, focal neurological signs, or a family history of early-onset dementia. For most patients presenting with poor concentration, the answer is in the labs, the sleep history, or the pill bottle.